

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol		
Cordova Ashley			9/1/2020		NovoCure Ltd [NVCR]		
(Last) (First) (Middle)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <b>Chief Financial Officer /</b>				
(Street)			5. If Amendment, Date Original Filed(MM/DD/YYYY)		6. Individual or Joint/Group Filing(Check Applicable Line)		
MALVERN, PA 19355					<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)							

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	7348	D	
Restricted Share Units	1465 (1)	D	
Restricted Share Units	1006 (2)	D	
Restricted Share Units	5314 (3)	D	
Restricted Share Units	5405 (4)	D	
Restricted Share Units	5904 (5)	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Options to Buy Ordinary Shares	(6)	4/22/2025	Ordinary Shares	13840.0	\$15.6	D	
Options to Buy Ordinary Shares	(6)	2/24/2026	Ordinary Shares	8936.0	\$11.46	D	
Options to Buy Ordinary Shares	(6)	7/27/2026	Ordinary Shares	2480.0	\$11.44	D	
Options to Buy Ordinary Shares	(7)	2/21/2027	Ordinary Shares	9752.0	\$7.15	D	
Options to Buy Ordinary Shares	(8)	3/21/2029	Ordinary Shares	14595.0	\$47.04	D	
Options to Buy Ordinary Shares	7/26/2021	7/25/2027	Ordinary Shares	7500.0	\$19.25	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<b>Options to Buy Ordinary Shares</b>	<a href="#">(9)</a>	<b>2/26/2028</b>	<b>Ordinary Shares</b>	<b>16051.0</b>	<b>\$21.5</b>	<b>D</b>	
<b>Options to Buy Ordinary Shares</b>	<a href="#">(10)</a>	<b>10/29/2028</b>	<b>Ordinary Shares</b>	<b>8300.0</b>	<b>\$32.02</b>	<b>D</b>	
<b>Options to Buy Ordinary Shares</b>	<a href="#">(11)</a>	<b>3/2/2030</b>	<b>Ordinary Shares</b>	<b>10422.0</b>	<b>\$69.37</b>	<b>D</b>	
<b>Options to Buy Ordinary Shares</b>	<a href="#">(12)</a>	<b>8/31/2030</b>	<b>Ordinary Shares</b>	<b>11336.0</b>	<b>\$84.68</b>	<b>D</b>	

**Explanation of Responses:**

- (1) Represents restricted share units that are scheduled to vest on February 27, 2021, subject to the reporting person's continued employment through such date.
- (2) Represents restricted share units that are scheduled to vest in equal installments on each of October 30, 2020 and 2021, subject to the reporting person's continued employment through such dates.
- (3) Represents restricted share units that are scheduled to vest in equal installments on each of March 22, 2021 and 2022, subject to the reporting person's continued employment through such dates.
- (4) Represents restricted share units that are scheduled to vest in equal installments on each of March 3, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.
- (5) Represents restricted share units that are scheduled to vest in equal installments on each of September 1, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.
- (6) Currently exercisable.
- (7) Options to buy 9,752 ordinary shares, 2 shares of which are currently exercisable and the remainder vest on February 22, 2021.
- (8) Options to buy 14,595 ordinary shares, 3,649 shares of which are currently exercisable and the remaining 10,946 shares of which will vest and become exercisable in equal installments on each of March 22, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates.
- (9) Options to buy 16,051 ordinary shares will vest and become exercisable in equal installments on each of February 27, 2021 and 2022, subject to the reporting person's continued employment through such dates.
- (10) Options to buy 8,300 ordinary shares will vest and become exercisable in equal installments on each of October 30, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates.
- (11) Options to buy 10,422 ordinary shares will vest and become exercisable in equal installments on each of March 3, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.
- (12) Options to buy 11,336 ordinary shares will vest and become exercisable in equal installments on each of September 1, 2021, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
<b>Cordova Ashley C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN, PA 19355</b>			<b>Chief Financial Officer</b>	

**Signatures**

By: /s/ Steven Robbins, Attorney in Fact for Ashley Cordova

9/10/2020

--Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.